Presentation on theme: "Type of BPCA Supplement Lead CTSA InstitutionProject Lead Primary CTSA Committee AlignmentCollaborating CTSA Institutions Development of a pharmacokinetic."— Presentation transcript:
Type of BPCA Supplement Lead CTSA InstitutionProject Lead Primary CTSA Committee AlignmentCollaborating CTSA Institutions Development of a pharmacokinetic algorithm to improve outcomes in Neonates DukeDanny BenjaminCC-Child Health Oversight Committee UT-SW, Case-Western RU, UCSD Advanced MRI to assess neonatal care and outcome UTHSCNehal ParikhCC-Child Health Oversight Committee UT-MB (Galveston) Improving Pediatric Outcomes Through Cost- Effective Management of the Neonatal Abstinence Syndrome Utah Center for Clinical & Translational Science Robert WardCC-Child Health Oversight Committee Case Western RU (also PPRU) Cardiac Outcome Measures for Pediatric Muscular Dystrophy Research U PittsburghPaula ClemensCC-Child Health Oversight Committee Washington University, UC-Davis, UT- Houston, CNMC Improving Outcome Measures for chronic lung disease of prematurity UNCWayne PriceCC-Child Health Oversight Committee Duke, Stanford, Iowa, UAB, U-CO, Ohio State, Yale, U Chicago, Virginia Commonwealth University Development of a small volume PK, PD, PG sampling technique for fentanyl in preterm and term neonates with and without cyanotic congenital heart disease U-COJeff Galinkin (U-CO), Greg Hammer (Stanford) CC-Child Health Oversight Committee U-Cin, Stanford, U Chicago, U-Penn (CHOP), CNMC A Toolbox of Outcome Measures for Targeted Treatment Trials in Children UC-DavisRandi HagermanCC-Child Health Oversight Committee U-Wash, U-CO, Duke, U-WI Measuring Sleep in Autism: Use of Wireless, Comfortable, and Home-Based Tools VanderbiltBeth MalowCC-Child Health Oversight Committee JHU, U-CO Pediatric Cardiac Intensive Care Research Consortium and Data Standards Repository U-MI Ann ArborJames GurneyCC-Child Health Oversight Committee Stanford, UCSF, Harvard, Medical College of Wisconsin, Seattle Children's Hospital 2009 BPCA Administrative Supplements
Type of BPCA Supplement Lead CTSA InstitutionProject Lead Primary CTSA Committee AlignmentCollaborating CTSA Institutions Methadone vs. Morphine PD/PD in infants and young children after cardiac surgery StanfordGreg HammerCC-Child Health Oversight Committee Indiana U, OSHU, U-CO Clinical and Genetic Predictors of Vincristine- induced peripheral neuropathy IndianaJamie RenbargerCC-Child Health Oversight Committee Vanderbilt, U-MI Ann Arbor, GWU (now with CNMC CTSA) Nasal Potential Difference Studies Utilizing CFTR Modulators UABSteven RoweCC-Child Health Oversight Committee CWRU, Wash U, Methodological Improvement in Measuring Efficacy Outcomes in Antihypertensive Trials in Children CWRUJeff BlumerCC-Child Health Oversight Committee U-Cincinnati, Arkansas Children's Hospital, UCSD Effect of BMI on Exposure-Response Relationships to Lisinopril in Children CWRUJeff BlumerCC-Child Health Oversight Committee U-Cincinnati Advancing Patient Reported Outcomes (PROs) in children with Cystic Fibrosis U WashChristopher GossCC-Child Health Oversight Committee UNC, Pittsburgh, Pediatric hypertension outcome measuresAECOMFred KaskelCC-Child Health Oversight Committee Weill Cornell, Columbia, Yale, U Rochester Improving BPD predictors and outcomes for clinical trials TuftsJon DavisCC-Child Health Oversight Committee Ohio State, Harvard Targets and Barriers for Hydroxyurea Therapy in Sickle Hemoglobinopathies Columbia UniversityNancy GreenCC-Child Health Oversight Committee Albert Einstein COM, Yale, UCSF/Oakland, Weill-Cornell, U Rochester 2009 BPCA Administrative Supplements
Your consent to our cookies if you continue to use this website.